Jose Arribas
Jose Arribas
Hospital La Paz
Dirección de correo verificada de
Citado por
Citado por
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant, E DeJesus, JR Arribas, AL Pozniak, B Gazzard, RE Campo, ...
New England Journal of Medicine 354 (3), 251-260, 2006
Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection
S Walmsley, B Bernstein, M King, J Arribas, G Beall, P Ruane, M Johnson, ...
New England Journal of Medicine 346 (26), 2039-2046, 2002
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ...
Clinical Infectious Diseases 51 (8), 963-972, 2010
Evaluation of convalescent plasma for Ebola virus disease in Guinea
J Van Griensven, T Edwards, X de Lamballerie, MG Semple, P Gallian, ...
New England Journal of Medicine 374 (1), 33-42, 2016
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
JR Arribas, AL Pozniak, JE Gallant, E DeJesus, B Gazzard, RE Campo, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (1), 74-78, 2008
Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ...
The Journal of infectious diseases 210 (3), 354-362, 2014
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and …
AL Pozniak, JE Gallant, E DeJesus, JR Arribas, B Gazzard, RE Campo, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 43 (5), 535-540, 2006
Clinical management of Ebola virus disease in the United States and Europe
TM Uyeki, AK Mehta, RT Davey Jr, AM Liddell, T Wolf, P Vetter, ...
New England Journal of Medicine 374 (7), 636-646, 2016
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised …
J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, B Young, ...
The Lancet infectious diseases 12 (2), 111-118, 2012
Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
M Pérez-Olmeda, M Núñez, M Romero, J González, A Castro, JR Arribas, ...
Aids 17 (7), 1023-1028, 2003
Cytomegalovirus encephalitis
JR Arribas, GA Storch, DB Clifford, AC Tselis
Annals of internal medicine 125 (7), 577-587, 1996
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial
AR Lifson, J Neuhaus, JR Arribas, M van den Berg-Wolf, AM Labriola, ...
American journal of public health 100 (10), 1896-1903, 2010
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active …
A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ...
The Lancet Infectious Diseases 16 (1), 43-52, 2016
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
JR Arribas, A Horban, J Gerstoft, G Fätkenheuer, M Nelson, N Clumeck, ...
Aids 24 (2), 223-230, 2010
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
JJ Eron Jr, JK Rockstroh, J Reynes, J Andrade-Villanueva, ...
The Lancet infectious diseases 11 (12), 907-915, 2011
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical …
JR Arribas, F Pulido, R Delgado, A Lorenzo, P Miralles, A Arranz, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (3), 280-287, 2005
Assessment of second-line antiretroviral regimens for HIV therapy in Africa
NI Paton, C Kityo, A Hoppe, A Reid, A Kambugu, A Lugemwa, ...
New England journal of medicine 371 (3), 234-247, 2014
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
F Pulido, JR Arribas, R Delgado, E Cabrero, J González-García, ...
Aids 22 (2), F1-F9, 2008
Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 …
F Raffi, AG Babiker, L Richert, JM Molina, EC George, A Antinori, ...
The Lancet 384 (9958), 1942-1951, 2014
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in …
P Cahn, J Andrade-Villanueva, JR Arribas, JM Gatell, JR Lama, M Norton, ...
The Lancet Infectious Diseases 14 (7), 572-580, 2014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20